Your breath smells and we can use this smell to detect breast cancer. Breath analysis is an emerging technology that can inexpensively quickly, painlessly and non-invasively screen women for breast cancer. This is an important life saving tool because breast cancer is the most common cancer in women, with 2.4 million women diagnosed globally in 2021. Unfortunately, millions of women are NOT screened because a mammogram exam is simply not accessible. As a result, 70% of all breast cancer cases in the world are diagnosed at stage 3 or later, diminishing a woman’s chances of surviving this disease. Breath analysis is staked to revolutionize breast cancer diagnosis enabling women to get treated while their cancers are still curable.
The Mammogram is the gold standard for breast cancer screening. Yet women, too many women avoid the mammogram. It is invasive and painful. Other women live too far away and cannot be away from her family and home for a day to travel to an imaging center. Others cannot afford the cost of a mammogram.
Pulmostics LTD is a world leader in breath analysis diagnostic systems using advanced biomarker analytical technology and data analysis algorithms. Breath analysis for disease diagnosis has a long history and is rapidly emerging as an effective diagnostic tool, benefited from the development of vapor analysis technology.
We have developed BreathSense™ 1000 for detecting breast cancer. Our system captures patient breath, identifies characteristic biomarkers for breast cancer, and analyzes the signal pattern with high sensitivity and accuracy. The technology can accomplish each diagnosis in just a few minutes on site, instead of hours or even days waiting for results. It is also non-invasive, painless, affordable and can be administered at point of care – i.e. doctor’s office. One breath and five minutes is all it takes.
Breath analysis has been demonstrated in clinical trials to be able to detect breast cancer with a sensitivity and specificity that is similar to a mammogram. We are seeking funding to conduct large scale clinical trial to obtain the regulatory approvals so this novel painless easy to use technology can be widely used to help provide screening to the million of women who do not
Funds will be used to pay for the cost of a clinic trial in Mexico. The breakdown is the following:
Hospital charges 95,000
Testing instruments 60,000
Data collection 60,000
Clinical trial audit 100,000
Statistical Analysis 100,000
Outside laboratory services 85,000
We have contracted with Christus Muguerza hospitals Monterey Mexico to provide patients and facilities. We have recruited a talented oncologist associated with Christus Muguerza hospital as the primary investigator. The BreathSense™ 1000 is developed and we have the breath capture devices ready to go.
We have initiated discussions with investors and distribution partners. Discussions are underway with equity investors and other private charities to provide operating funding and clinical trial funds.
Breast cancer is the most frequently diagnosed cancer today. The number of cases of breast cancer cases are increasing at an alarming rate. In some countries the rate of increase exceeds 2% per annum. In the absence of a screening technology that overcomes the current barriers: cost, pain and invasive x-rays, women will continue to not be screened. The death rate from breast cancer will continue its inexorable climb. This is unacceptable. If implemented at a global scale, we believe BreathSense™ 1000 could help save lives of women around the world.
Mr. William Wittmeyer has 30+ years experience with technology companies, William is the Founder and Chief Executive Officer of Pulmostics. William has successfully launched and led numerous technology companies through full life cycle from start up to IPO. William has provided critical leadership and management to companies such as Exxon, WR Grace, Wittham, eXS, China Campus Wireless Networks and Electronic Sensor Technology. William holds a B.S. from the US Coast Guard Academy and an MBA from Columbia Graduate School of Business.
Mr. Bernard Picot has 25+ years of global experience with technology companies. Bernard incepted, funded and led several technology companies and organizations to success, from ground-up. He launched over 15 new disruptive product lines across the globe for corporations such as Dell, CompuAdd Computer Corporation, IBM, Intermec Systems, Proxim inc,
RapidWave Inc, NextSense and now Pulmostics LTD. Bernard holds a Bachelor degree in Electrical Engineering.
Dr. Yin Sun is the Chief Technology Officer of Pulmostics. He has been involved with the research and development of trace chemical detection for over 23 years. He has significant experience in vapor and trace chemical detection including instrumentation, data analysis and application development across medical, homeland security, food and environmental
applications. Dr. Sun has authored two highly recognized books on trace chemical detection and applications. Dr. Sun holds a PH.D. from the University of Connecticut.
Dr. Jorge Leon is an internationally recognized expert and pioneer in the development and commercialization of clinical molecular diagnostics. Dr. Leon has a PhD in Cellular and Molecular Biology from NYU and completed his post doctoral studies at the German Cancer Research Center in Heidelberg, Germany and Columbia University in NYC. Dr. Leon played an
integral role in the founding and growing of the molecular diagnostics laboratories at Quest Diagnostics Incorporated. During his twelve-year tenure focused on building the Quest Diagnostic molecular menu and driving the molecular diagnostics strategy, which today is the largest molecular diagnostics service laboratory in the world with over 1.5 billion in revenues.
Company Website: Pulmostics
Your contribution: in support of ""
Add a comment (optional):
120 Character(s) Remaining